For research use only. Not for therapeutic Use.
Spesolimab (BI 655130) is an anti-IL-36R antibody. IL-36 involves in immune system, as Spesolimab can be used for palmoplantar pustulosis (PPP) research. Spesolimab is associated with the reduction of biomarkers linked to innate, Th1/Th17, and neutrophilic pathways[1][2].
| Catalog Number | I042200 |
| CAS Number | 2097104-58-8 |
| Purity | ≥95% |
| Reference | [1]. Mrowietz U, et al. Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. Dermatol Ther (Heidelb). 2021 Apr;11(2):571-585. [2]. Geller S, et al. CCR4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders and its implications for diagnosis and treatment[C]//Journal of Investigative Dermatology. STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA: ELSEVIER SCIENCE INC, 2019, 139(9): B25-B25. |
